Physician profile
Eric Stephen Rutstein
NPI 1639265333
$24,470.94
in general payments reported to CMS, 2019-2025
34 companies · $2,900 in 2025
The $2,900 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,010 · 2020: $1,832 · 2021: $2,687 · 2022: $3,266 · 2023: $8,372 · 2024: $3,403 · 2025: $2,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,125.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,550.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,531.07 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $2,333.88 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,080.83 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $2,004.62 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $1,127.11 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $922.89 | 2020-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $904.73 | 2019-2025 | Wellbutrin, Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $856.84 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $828.11 | 2019-2022 | |
| Allergan, INC. | $820.00 | 2019-2020 | |
| Almatica Pharma LLC | $819.62 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Axsome Therapeutics, INC. | $804.49 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $801.64 | 2021-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $492.60 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $469.48 | 2019-2025 | Spravato |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $351.67 | 2022-2024 | Quviviq |
| Corium, LLC | $306.33 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $271.59 | 2021-2023 | Belsomra |
| Eisai INC. | $209.40 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $202.03 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $156.60 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $149.28 | 2021-2025 | Cobenfy |
| Adlon Therapeutics L.P. | $125.79 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $123.26 | 2021 | |
| Noven Pharmaceuticals, INC. | $122.50 | 2024 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $122.11 | 2022-2024 | Qelbree |
| Jazz Pharmaceuticals INC. | $114.96 | 2019-2022 | |
| Noven Therapeutics, LLC | $105.31 | 2021-2024 | Xelstrym, Secuado |
| Neos Therapeutics, Lp | $97.54 | 2019-2024 | Adzenys Xr-Odt |
| Neuronetics, INC. | $77.75 | 2019 | |
| Currax Pharmaceuticals LLC | $46.11 | 2022-2024 | Contrave, Onzetra Xsail |
| Shire North American Group INC | $36.04 | 2019 | |
| Alfasigma USA, INC. | $35.12 | 2021 | |
| Arbor Pharmaceuticals, INC. | $19.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Rutstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.